Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 12Pain 10Bone Neoplasms 8Breast Neoplasms 7Humoral Hypercalcemia Of Malignancy 2Prostatic Neoplasms 1Osteoporosis 1Multiple Myeloma 1Lung Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1Bone Diseases, Metabolic 1Adenocarcinoma 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Ibandronic Acid × Clear all
NCT00492843 2016-02-17

Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

Chinese Society of Lung Cancer

Phase 4 Terminated
20 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡